

Taiwanese Companies Profiles

Australia-Taiwan Clinical Trials and Biotech Forum 28 July 2023

Company	Alar Pharmaceuticals Inc. / 昱展新藥生技股份有限公司
Company Website	https://alarpharm.com/
YouTube Link	https://youtu.be/zas3D3KSbQQ
Company Profile	Alar Pharmaceuticals Inc. is a Taiwan-based new drug development company, focusing on developing long-acting release injectables (LAIs) for treating central nervous system disorders, which mainly include opioid use disorder, alcohol use disorder, chronic pain, treatment-resistant depression, and Parkinson's disease. Our LAIs have distinctive characteristics such as low viscosity, small injection volume, and smooth drug release profile with fewer side effects, which provide better medication choices to patients.

Company Name (both English and Chinese)	AltruBio, Inc. / 全心醫藥生技股份有限公司
Company Website	https://www.altrubio.com/altrubio/en
YouTube Link	https://youtu.be/AiUISpio_5w
Company Profile	AltruBio is developing first-in-class immune checkpoint enhancer (ICE) to target diseases of the immune system. We have a growing pipeline of differentiated and innovative biologic drug products for immune mediated diseases of inflammation at various stages of clinical development. Our world-class global team brings a breadth of expertise in immunology and drug development to bring our biologic treatments to patients.

Company	Gongwin Biopharm Co., Ltd. / 共信醫藥科技股份有限公司
Company Website	https://gongwinbiopharm.com/
Company Profile	<p>Gongwin Biopharm Co., Ltd. is a Taiwan-based biopharmaceutical company focused on developing novel anti-cancer drugs. In 2017, Gongwin-KY has been granted the “Biotech New Drug Company” designation by MOEA, Taiwan, and became a public trading company at Taipei Emerging Stock Board.</p> <p>Gongwin adopts an innovative Tumor ablation therapy called MITTA therapy - “minimally-invasive targeted tumor ablation” for the treatment of focal malignancies. Our proprietary core technology is an intratumoral injection of our API - PTS (para-toluene sulfonamide) that is administered using existing diagnostic and minimally-invasive intervention techniques, which is a unique and distinct way of treating focal malignancies in the current market.</p> <p>PTS has been newly listed in the pharmacopeia of China and received marketing approval from NMPA (China) for treating Severe Malignant Airway Obstructions in Non-Small Cell Lung Carcinomas (NSCLC) in 2022.</p>

Company	Lin BioScience, Inc. / 仁新醫藥股份有限公司
Company Website	https://www.linbioscience.com/
YouTube Link	https://www.youtube.com/watch?v=vgqx5c6kea8
Company Profile	<p>Lin BioScience, Inc. (TPEx: 6696) is a drug development company established in 2016 focusing on advancing novel therapies and first-in-class treatments for unmet medical needs in various therapeutic areas such as ophthalmology, oncology, and metabolic diseases. Lin BioScience’s pipeline currently consists of four candidate drugs. LBS-008 treating dry age-related macular degeneration and Stargardt disease, and LBS-009 treating nonalcoholic steatohepatitis are developed by its subsidiary Belite Bio Inc. (Nasdaq: BLTE). LBS-007 treating acute leukemias and solid tumors, and LBS-002 treating glioblastoma and the metastasis are developed by Lin BioScience, inc..</p>

Company Name	MegaPro Biomedical Co., Ltd. / 巨生生醫股份有限公司
Company Website	https://www.megaprobio.com/
Company Profile	<p>Founded in 2015, MegaPro (Taiwan OTC Stock Code: 6827) is a clinical-stage specialty pharmaceutical company, focused on nanomedicine development. Our mission is to develop innovative nanomedicine to improve the therapeutic/diagnostic efficacy, safety profiles and the quality of life for patients. Two proprietary technology platforms with comprehensive global patent portfolio have been established including: (A) PEGylated Iron Oxide nanoparticles (IOP Injection) and (B) Polymer-based Nano-Micelles. These platforms are utilized in our clinical projects as</p> <ul style="list-style-type: none"> • MPB-1514: A high-dose intravenous iron with better potency and safety profile for treating Iron Deficiency Anemia (completed phase 2a in US) • MPB-1523: A MRI contrast agent for hepatocellular carcinoma diagnosis. (Ready for phase 3) • MPB-2043: A MRI contrast agent for the diagnosis of lymph node metastasis (Phase 2 study will be initiated in Q4/2023) • MPB1734: Taxane nanoformulation for treatment of advanced solid tumors (Currently under Phase 1/2a study in Taiwan and US)